ArticleLeukemia2012

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.

Z-X Cao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.